Market closed

Sarepta Therapeutics/$SRPT

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Sarepta Therapeutics

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.

Ticker

$SRPT
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Cambridge, United States

Employees

1,314
Website
www.sarepta.com

SRPT Metrics

BasicAdvanced
$11B
97.09
$1.22
0.80
-

$11B

0.8

$173.25

$102.16

785K

3.839

2.451

106.953

115.87

4.23%

1.51%

12.27%

97.088

6.999

9.26

9.48

-23.899

48.45%

-115.61%

36.46%

-41.57%

What the Analysts think about SRPT

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Sarepta Therapeutics stock.

SRPT Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

SRPT Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

SRPT News

AllArticlesVideos
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue

Business Wire·2 days ago
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire·2 weeks ago
Sarepta wins $115.2 million US drug patent verdict from Japan's Nippon Shinyaku

Sarepta wins $115.2 million US drug patent verdict from Japan's Nippon Shinyaku

Reuters·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SRPT

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Sarepta Therapeutics stock?

Sarepta Therapeutics (SRPT) has a market cap of $11B as of January 15, 2025.

What is the P/E ratio for Sarepta Therapeutics stock?

The price to earnings (P/E) ratio for Sarepta Therapeutics (SRPT) stock is 97.09 as of January 15, 2025.

Does Sarepta Therapeutics stock pay dividends?

No, Sarepta Therapeutics (SRPT) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Sarepta Therapeutics dividend payment date?

Sarepta Therapeutics (SRPT) stock does not pay dividends to its shareholders.

What is the beta indicator for Sarepta Therapeutics?

Sarepta Therapeutics (SRPT) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.